Big news in the biopharma sector as INCOG BioPharma Services has announced a $200 million expansion to its existing manufacturing facility in Fishers, Indiana. The company, which specializes in contract development and manufacturing of injectable drugs, plans to grow its workforce to nearly 1,000 employees by 2030. This move is set to significantly bolster the company's manufacturing capabilities, responding to the growing demand from its global partners.
With the heavy lifting aimed at increasing their injectable drug product manufacturing capacity, INCOG BioPharma is betting big on the future. Cory Lewis, CEO of INCOG BioPharma, told City of Fishers officials, "Committing another $200 million and employing nearly 1,000 team members by 2030 underscores our dedication to continue providing worldclass, flexible manufacturing capacity while creating generational opportunities for the talented workforce here in central Indiana." The expansion is a clear indication of the robust health of the life sciences industry in the region.
Indiana Governor Mike Braun expressed his approval of the expansion, highlighting it as a testament to Indiana's growing influence in the life sciences and manufacturing sectors. In a statement obtained by the City of Fishers, Governor Braun praised the major investment for positioning Indiana as one of the nation's top hubs for innovative drug development and for its potential to introduce hundreds of new, high-paying jobs.
The new expansion, scheduled to begin early 2026, will not only grow the INCOG campus to a global manufacturing hub but also give a sizeable boost to the local economy. Thrilled about the expansion, Mayor of Fishers Scott Fadness reaffirmed the city's commitment to becoming a life science epicenter. "This massive new investment and the commitment to nearly 1,000 high-paying jobs will have a transformative impact on our community’s economic landscape for decades to come," Fadness told the City of Fishers, signaling continued growth and investment in the sector.
Committed to innovation and high-quality standards, INCOG plans to utilize the investment to implement advanced manufacturing infrastructure. This enhancement will not only amplify its sterile fill/finish of injectable drug product but also enable the company to increase production up to 480 million units per year. Moreover, INCOG's track record as one of Indiana's Best Places to Work for four consecutive years complements the promise of creating skilled positions across various critical departments such as operations, engineering, quality, and administration.
